Impact on the Oxidative Stress of the Different Analogues of Insulin in People With Type 1 Diabetes. (Ineox Study)

• Status: Unknown status
• Trial end date: 2019-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This study evaluates in a group of people with DM 1 the influence in parameters of oxidative stress of the treatments with the different current analogs of insulin

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
• Treatments: Insulin; Insulin Aspart; Insulin degludec, insulin aspart drug combination; Insulin Glargine; Insulin glulisine; Insulin Lispro; Insulin, Globin Zinc; Insulin, Long-Acting

Criteria

Inclusion Criteria:

• Age between 18 years and 65 years (inclusive).

• DM1 of more than two years of evolution with habitual follow-up in the Diabetes Unit of the University Regional Hospital of Malaga.

• HbA1c ≤ 10%

• Intensive treatment with basal MDI - Bowl for more than 12 months prior to the start of study.

• Gives informed consent.

Exclusion Criteria:

• Chronic kidney disease, liver disease, thyroid dysfunction (except hypothyroidism correctly treated and controlled).

• Pregnancy or pregnancy planning.

• Diabetes mellitus type 2.

• Hyperuricemia (uric acid ≥7 mg / dl at the time of inclusion or current treatment With allopurinol).

• Absence of collaboration (informed consent).